Regardless, our results substantiate that such targeting can offer superior anti-tumor efficacy in malignancies that are especially sensitive to LSD1 inhibitors such as erythroleukaemia, acute myeloid leukemia as well as in other cancers such as multiple myeloma. The gene discussed is KDM1A; the disease is acute myeloid leukemia.